<DOC>
	<DOCNO>NCT01784588</DOCNO>
	<brief_summary>The purpose research study compare treatment device ( Solyx ) different mesh sling control device ( Obtryx II ) treatment symptom SUI . Safety information patient outcomes collect three ( 3 ) year evaluate .</brief_summary>
	<brief_title>Post Market Study Of Single Incision Sling Versus Transobturator Sling Stress Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>1 . Female ≥ 18 year age 2 . Willing able comply study procedure provide write informed consent participate study ( subject legal representative ) 3 . Diagnosed predominant SUI confirm positive cough stress test protocol require bladder fill procedure ( see manual operation ) 4 . Confirmed SUI great urge incontinence MESA 5 . Cystometric capacity ≥ 300 cc 6 . Postvoid residual ( PVR ) ≤ 150 cc 7 . Medically approved general , regional monitor anesthesia 1 . Subjects pregnant , lactating , planning future pregnancies 2 . Subjects chief complaint overactive bladder 3 . Subjects pattern recurrent urinary tract infection , define ≥ 2 cultureproven urinary tract infection 6month period prior surgery ≥ 3 12month period 4 . Subjects previous surgical procedure SUI include bulking , urethral sling , bone anchor , Burch procedure , pubovaginal sling , MMK procedure . Excluding Kelly plication , Botox , anterior repair , InterStim 5 . Subjects prior pelvic organ prolapse surgery experience mesh complication 6 . Subjects previous radiation therapy pelvis 7 . Subjects know suspected hypersensitivity polypropylene mesh 8 . Subjects follow confound condition : 1 . Neurogenic bladder 2 . Urethral stricture bladder neck contracture 3 . Bladder stone tumor 4 . Urinary tract fistula diverticulum 5 . Pathology would compromise implant placement include subject currently take anticoagulation therapy 6 . Pathology would limit blood supply infection would compromise heal include chemotherapy , systemic steroid systemic immunosuppressant 9 . Subjects diabetes A1c ≥ 7 % 10 . NonEnglish speaking subject 11 . Subjects participate investigational study ( medical device drug ) within 30 day study entry may impact analysis device previously participate current study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>